Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIRMELLA 7/7/7 vs LEVORA 0.15/30-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Also induces changes in cervical mucus (increasing viscosity) and endometrium (reducing receptivity) to impair sperm penetration and implantation.
Treatment of chronic hepatitis C virus (HCV) genotype 1 infection in combination with other antiviral agents
Prevention of pregnancy
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 placebo tablets).
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Ethinyl estradiol: 13-27 hours (terminal); Levonorgestrel: 11-45 hours (terminal, dose-dependent due to SHBG binding).
Primarily metabolized by CYP3A4; also undergoes glucuronidation via UGT1A1. It is a substrate of P-glycoprotein.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use is not recommended due to potential fluid retention and hormonal accumulation.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment or end-stage renal disease due to potential for fluid retention and hyperkalemia.
None
PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major birth defects; however, inadvertent use in early pregnancy is not associated with teratogenicity. Second and third trimesters: Not indicated for use; animal studies show no teratogenic effects, but data in humans are insufficient. Overall, the FDA assigns a Pregnancy Category X due to the lack of need during pregnancy and potential fetal harm from hormonal exposure (e.g., masculinization of female fetuses with progestins).
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (limb defects, cardiac anomalies, feminization of male fetuses). Administration during first trimester associated with major birth defects. Second and third trimester exposure may cause fetal adrenal suppression and withdrawal bleeding. Use is not indicated during any trimester.
PIRMELLA 7/7/7 is a prenatal vitamin formulation containing 7 key vitamins and minerals each at 7 mg or mcg doses. Notably, it includes iron (7 mg) and folic acid (7 mcg). The low iron dose may be insufficient for patients with anemia; consider additional supplementation. Folic acid at 7 mcg is below standard prenatal recommendation (400-800 mcg); ensure patient is on an additional folic acid supplement. The '7/7/7' suggests equal dosing of three components—likely folic acid, iron, and calcium—but verify actual constituents. Do not exceed recommended daily intake; some multivitamins contain toxic doses of fat-soluble vitamins.
Contains ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg. 28-day regimen: 21 active tablets followed by 7 placebo. Efficacy depends on adherence. Consider alternative contraception if patient is on enzyme-inducing anticonvulsants (e.g., carbamazepine, phenytoin) or certain antibiotics (rifampin). Missed pill protocol: if one active pill missed, take as soon as remembered and continue schedule; if two missed, take two pills for two days and use backup contraception for 7 days. Contraindicated in patients with history of DVT, PE, stroke, MI, migraine with aura (especially if age >35), breast cancer, hepatic tumors, uncontrolled hypertension, or pregnancy.
No interactions on record
No interactions on record
Common clinical questions about PIRMELLA 7/7/7 vs LEVORA 0.15/30-28, answered by our medical review team.
PIRMELLA 7/7/7 is a Oral Contraceptive that works by Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.. LEVORA 0.15/30-28 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Also induces changes in cervical mucus (increasing viscosity) and endometrium (reducing receptivity) to impair sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIRMELLA 7/7/7 and LEVORA 0.15/30-28 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIRMELLA 7/7/7 is: PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.. The standard adult dose of LEVORA 0.15/30-28 is: One tablet orally once daily at the same time each day for 28 days (21 active tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 placebo tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIRMELLA 7/7/7 and LEVORA 0.15/30-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIRMELLA 7/7/7 is classified as Category C. PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major b. LEVORA 0.15/30-28 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (limb defects, cardiac anomalies, feminization of male fetuses). Administration during first trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Levonorgestrel: Hepatic metabolism via reduction to tetrahydro derivatives, then conjugation with sulfate and glucuronide. CYP3A4 involved. Ethinyl estradiol: Hepatic metabolism via hydroxylation by CYP3A4, followed by methylation and conjugation (glucuronide/sulfate). Undergoes enterohepatic recirculation.
Renal: 70% unchanged; fecal: 30% as metabolites.
Renal: ~50% (as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel); Fecal: ~50% (enterohepatic recirculation).
95% bound to albumin and alpha-1-acid glycoprotein.
Ethinyl estradiol: 97-98% bound to albumin; Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG).
1.2 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: 2.5-4.0 L/kg; Levonorgestrel: 1.8-2.6 L/kg (distribution to breast tissue, reproductive organs, and fat).
Oral: 45% (first-pass metabolism). Intravenous: 100%.
Ethinyl estradiol: ~40-50% (first-pass metabolism); Levonorgestrel: ~95-100% (minimal first-pass effect).
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment is established.
Contraindicated in decompensated cirrhosis (Child-Pugh class B or C). Use with caution in mild hepatic impairment (Child-Pugh class A) with careful monitoring; consider alternative contraception.
Not indicated for use before menarche. For postmenarchal adolescents, dosing is the same as adults: one tablet daily for 28 days.
Postmenarchal adolescents: One tablet orally once daily per adult dosing schedule. Safety and efficacy established in females of reproductive age.
Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke or have cardiovascular risk factors.
Not indicated for postmenopausal women. No specific dosing adjustments; efficacy and safety not established in women over 40 years of age due to declining fertility and increased thrombotic risk.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combined oral contraceptive use, especially in women over 35 years of age and heavy smokers (>15 cigarettes/day). Women who use combined oral contraceptives should be strongly advised not to smoke.
Increased risk of venous thromboembolism (VTE) and arterial thrombosis (e.g., stroke, MI), especially in smokers, obese patients, and those with hypertension. Discontinue if thrombotic event occurs. Risk of hepatic neoplasia (benign/malignant). Elevated blood pressure; monitor regularly. Gallbladder disease. Carbohydrate/lipid metabolism effects; monitor diabetic patients. Headache (including migraine); discontinue if new or worsening. Uterine bleeding irregularities. Retinal vascular thrombosis; discontinue if vision changes. Rule out pregnancy before initiation. Not recommended for use during pregnancy.
Hepatic neoplasia (benign or malignant), current or history of VTE (deep vein thrombosis, pulmonary embolism), cerebrovascular or coronary artery disease, hereditary or acquired thrombophilia, uncontrolled hypertension, diabetes with vascular involvement, headache with focal neurological symptoms (e.g., migraine with aura), smoking >15 cigarettes/day in patients ≥35 years old, jaundice or steroid-related cholestasis, pregnancy, hypersensitivity to any component, use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir (increased transaminases)
Calcium-rich foods (e.g., dairy, fortified juices) and antacids can inhibit iron absorption. Caffeine (coffee, tea) and tannins (tea) reduce iron absorption. Vitamin C enhances iron absorption; taking with orange juice may be beneficial. Avoid taking with high-fiber foods or whole grains immediately as they can bind minerals.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid excessive intake (more than 1 quart daily). St. John's wort may reduce contraceptive efficacy.
Combined hormonal contraceptives may reduce milk production and breast milk composition. The ethinylestradiol and drospirenone components are excreted in human milk in small amounts. The milk-to-plasma (M/P) ratio for ethinylestradiol is approximately 0.004 and for drospirenone is not well-established but likely low. Use during lactation is generally not recommended, especially in the first 6 weeks postpartum, due to potential effects on infant estrogen receptors. Alternative methods are preferred.
Safety category: L2 (limited data). Ethinyl estradiol and levonorgestrel are excreted in breast milk in small amounts. M/P ratio not established. May reduce milk production and quality. Use during lactation not recommended, especially in early postpartum period. Alternative contraception advised.
PIRMELLA 7/7/7 is contraindicated during pregnancy, thus no dosing adjustments are recommended. If pregnancy is confirmed, the medication should be discontinued immediately.
Contraindicated during pregnancy; no dose adjustments applicable as medication must be discontinued. Pharmacokinetic changes in pregnancy (increased clearance of steroids) are not relevant due to absolute contraindication.
Take exactly one tablet daily with food to reduce stomach upset.,This supplement contains low iron; you may need additional iron if you have anemia—consult your doctor.,Folic acid dose is very low (7 mcg); ensure you take a separate folic acid supplement (400-800 mcg daily) as advised by your physician.,Do not take with dairy, antacids, or caffeine as they can reduce absorption.,Keep out of reach of children—iron overdose can be fatal.,Store in a cool, dry place away from moisture and heat.
Take one pill daily at the same time each day, preferably after a meal to reduce nausea.,Each pack contains 21 hormone pills (light pink) followed by 7 placebo pills (white); continue daily even during placebo week.,If you miss a dose, refer to the missed pill instructions in the package insert or consult your healthcare provider.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking, especially if over age 35.,Use backup contraception (e.g., condoms) if you miss pills or start vomiting/diarrhea within 4 hours of taking a pill.,Report any signs of blood clots: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature (20-25°C) away from moisture and heat.,If you are scheduled for surgery, inform your surgeon you are taking this medication as it may need to be stopped temporarily.,Consult your doctor before starting any new medications, including over-the-counter drugs and herbal supplements.